The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.
The blood-based test, called Melaseq, measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant.
The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
The firm has collected evidence supporting the use of its PancraGen to providing the same molecular information for samples from biliary strictures and solid pancreatic lesions as it has done for years in pancreatic cyst fluid.
Cigna began covering the company's ThyGeNext next-generation sequencing-based test for thyroid cancer risk assessment in 2017.
GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.
The company, which is also developing a therapeutic for the liver disease, plans to pursue regulatory approval in the US and Europe.
Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.
The collaborators are developing tests for rectal cancer based on microRNA and messenger RNA signatures.